+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tyrosine Kinase Inhibitors Market - Global Forecast to 2030- Product Image
Tyrosine Kinase Inhibitors Market - Global Forecast to 2030- Product Image
Sale

Tyrosine Kinase Inhibitors Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715482
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Tyrosine Kinase Inhibitors Market grew from USD 63.46 billion in 2024 to USD 68.21 billion in 2025. It is expected to continue growing at a CAGR of 7.14%, reaching USD 96.02 billion by 2030.

Executive Overview of the Tyrosine Kinase Inhibitors Landscape

The tyrosine kinase inhibitors (TKIs) market has emerged as a cornerstone of targeted therapy, delivering precision interventions across a spectrum of oncological and non-oncological conditions. Fueled by advances in molecular biology and a deeper understanding of signaling pathways, TKIs have transitioned from niche research tools to front-line therapeutics. This evolution reflects an industry-wide commitment to harnessing selective inhibition of tyrosine kinases to disrupt aberrant cell signaling with reduced off-target toxicity.

Early generations of TKIs focused primarily on Bcr-Abl fusion proteins in chronic myeloid leukemia, validating the concept of targeted blockade. Since then, innovations in molecule design have unlocked new classes of inhibitors-spanning EGFR, Her2 and VEGF targets-and broadened clinical applications into cardiovascular, endocrine and immunological disorders. As intellectual property lifecycles mature and competition intensifies, differentiation through novel delivery mechanisms, combination regimens and biomarker-driven patient stratification is paramount.

Against this dynamic backdrop, stakeholders-including pharmaceutical innovators, healthcare providers and policy makers-must navigate shifting regulatory landscapes, evolving reimbursement frameworks and complex supply-chain constraints. This report offers an executive synthesis of these forces, equipping decision-makers with actionable intelligence to capitalize on emerging trends and sustain growth in the increasingly competitive TKI domain.

Transformative Shifts Reshaping the Therapeutic Landscape

The TKI landscape is undergoing transformative shifts driven by breakthroughs in precision medicine, digitization of clinical workflows and an increasingly patient-centric approach to drug development. First, the integration of genomic and proteomic profiling into standard of care has enabled biomarker-guided trials, accelerating time to market for next-generation inhibitors and enhancing response rates by matching compounds to molecular signatures.

Second, decentralized and hybrid clinical trial models-leveraging telemedicine, remote monitoring and e-consent-have expanded patient access and optimized data integrity. By reducing geographical barriers, sponsors capture more diverse cohorts and refine safety profiles earlier in development.

Third, strategic collaborations between biopharma and technology companies are yielding AI-driven target discovery and predictive toxicology platforms. These partnerships shorten discovery timelines, mitigate late-stage failures and lower R&D expenditures.

Finally, regulatory agencies across North America, Europe and Asia-Pacific have introduced accelerated review pathways for therapies addressing critical unmet needs. These programs, coupled with adaptive trial designs and rolling submissions, empower sponsors to iterate rapidly and secure earlier approvals, reshaping competitive dynamics in the TKI sector.

Cumulative Effect of 2025 U.S. Tariffs on Market Dynamics

The imposition of new U.S. tariffs on active pharmaceutical ingredients and intermediates in 2025 has exerted a compounded influence on the TKI market. Import duties on certain chemical components have driven up input costs, prompting contract manufacturers and API suppliers to reevaluate sourcing strategies. As a result, several developers have negotiated long-term agreements with domestic producers to stabilize pricing and ensure supply continuity.

Concurrently, tariff-driven cost pressures have spurred sponsors to reassess geographic footprint, with some shifting final formulation and finish packaging operations to mitigate duties. This redistribution of manufacturing activities has sparked fresh investments in U.S. facilities, though offset by the need to retrain workforces and qualify new equipment under Good Manufacturing Practices.

Moreover, higher import costs have translated into modest price increases for certain TKI formulations, inviting scrutiny from payers and triggering intensified negotiations on rebate structures. To preserve margins, companies are implementing leaner supply-chain models, employing demand forecasting and strategic inventory buffers. In parallel, strategic collaborations with contract research organizations have been forged to accelerate scale-up and localize clinical supplies, preserving time to market despite tariff-related headwinds.

Granular Segmentation Insights for Strategic Positioning

In dissecting the TKI realm, six core dimensions reveal opportunities for precision positioning. Application area segmentation distinguishes non-oncological applications-addressing cardiovascular diseases, endocrine disorders and immunological conditions-from oncology submarkets, which span breast cancer, colorectal cancer, leukemia, lung cancer and lymphoma. This dual-axis focus underscores the versatility of kinase inhibition beyond tumor control into chronic disease management.

Product segmentation bifurcates the market into biologics and small molecules. Within biologics, fusion proteins and monoclonal antibodies command premium pricing and specialized administration, whereas small molecules range from first-generation agents to more selective second- and third-generation inhibitors, each successive iteration enhancing target specificity and resistance management.

Drug class segmentation comprises Bcr-Abl inhibitors, EGFR inhibitors (further dissected into first-line and second-line therapies), Her2 inhibitors and VEGF inhibitors. This taxonomy enables stakeholders to tailor clinical development strategies according to class-specific pharmacodynamics and competitive intensity.

End-user segmentation spans clinics, hospitals, laboratories and research institutes, with hospitals further differentiated into private and public entities, and laboratories categorized as academic or independent. This delineation informs distribution channel optimization and provider engagement models.

From a molecular perspective, dual-specificity protein kinases, serine/threonine kinases and tyrosine kinases (including receptor and non-receptor subfamilies) constitute distinct R&D silos, each demanding unique discovery platforms. Finally, distribution channel analysis evaluates hospital pharmacies, online pharmacies and retail pharmacies for product rollout and patient support services.

Regional Differentiators Driving Growth and Adoption

Regional dynamics shape TKI adoption patterns and growth trajectories. In the Americas, robust reimbursement frameworks, advanced oncology care networks and strong venture capital ecosystems support rapid uptake of innovative TKIs. Market leaders frequently pilot real-world evidence programs in major U.S. cancer centers, generating post-launch data that bolster payer negotiations and drive formulary inclusion.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and varying health-economics thresholds dictate differentiated market entry approaches. Western Europe’s centralized pricing negotiations contrast with emerging markets in the Middle East and Africa, where demand for affordable generics coexists with growing interest in biologics. Coordinated regional strategies often leverage adaptive reimbursement models and managed entry agreements to balance access with fiscal sustainability.

Across Asia-Pacific, government incentives for domestic manufacturing and expedited regulatory pathways have stimulated local R&D investment. Countries such as China, Japan and South Korea prioritize in-country clinical trials and technology transfer agreements, fostering regional research hubs. Meanwhile, patient advocacy groups and expanding insurance coverage continue to elevate the demand for targeted therapies.

Competitive Landscape and Key Player Dynamics

The competitive landscape features a blend of established pharmaceutical giants and agile innovators. AstraZeneca PLC and Bayer AG maintain leadership through diversified TKI portfolios and extensive global reach. Boehringer Ingelheim International and Bristol-Myers Squibb Company leverage robust pipelines and strategic acquisitions to reinforce class dominance.

Mid-tier and specialty players also exert influence: Cipla Limited and Lupin Limited drive market access in emerging economies with cost-effective generics, while Eisai Co. Ltd. and Spectrum Pharmaceuticals, Inc. focus on niche indications and combination regimens. F. Hoffmann-La Roche and Novartis AG continually optimize manufacturing scale and patent lifecycles to protect flagship compounds.

Multinational behemoths such as Eli Lilly and Company, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc. and Pfizer Inc. integrate TKIs into broader oncology ecosystems, exploiting cross-portfolio synergies. Meanwhile, companies like Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Steris Healthcare Pvt. Ltd. and Takeda Pharmaceutical Company Limited target regional markets with localized development and distribution strategies.

Actionable Recommendations for Industry Leaders

To thrive in an increasingly complex environment, industry leaders should prioritize four strategic imperatives. First, invest in next-generation resistance-overcoming molecules and biomarker discovery platforms to sustain differentiated pipelines. Collaboration with academic research centers and AI-driven biotech firms can accelerate early-stage innovation.

Second, diversify manufacturing footprints and secure flexible supply-chain partnerships to mitigate tariff exposure and geopolitical risks. Co-development agreements with contract manufacturers in tariff-exempt jurisdictions can preserve cost competitiveness and ensure uninterrupted product availability.

Third, tailor commercialization strategies to account for nuanced market access requirements across regions. Engage health-economics and outcomes researchers to generate robust real-world evidence, facilitating reimbursement negotiations and managed entry agreements in Europe, Middle East & Africa and Asia-Pacific.

Finally, integrate digital health solutions-from remote patient monitoring to AI-enabled adherence tools-to enhance therapeutic outcomes and generate high-value data. These offerings fortify payer relationships and elevate brand differentiation by demonstrating tangible improvements in patient quality of life.

Synthesis and Strategic Imperatives

The tyrosine kinase inhibitors sector stands at the confluence of scientific innovation, regulatory evolution and shifting commercial paradigms. The maturation of precision oncology and expanding non-oncological applications affirm the long-term potential of kinase-targeted therapies. Yet rising cost pressures, heightened competition and evolving payer expectations demand proactive adaptation.

By leveraging granular segmentation insights, companies can align R&D investments with high-value indications and optimize channel strategies to reach diverse end users. Meanwhile, a nuanced understanding of regional reimbursement environments enables targeted entry plans that balance access with profitability. Integrating digital health and real-world evidence capabilities further enhances market positioning and supports differentiated value propositions.

Ultimately, those who embrace flexible supply-chain models, foster cross-sector collaborations and harness emerging technologies will secure sustainable growth in this dynamic market.

Market Segmentation & Coverage

This research report categorizes the Tyrosine Kinase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Non-Oncological Applications
    • Cardiovascular Diseases
    • Endocrine Diseases
    • Immunological Disorders
  • Oncology
    • Breast Cancer
    • Colorectal Cancer
    • Leukemia
    • Lung Cancer
    • Lymphoma
  • Biologics
    • Fusion Proteins
    • Monoclonal Antibodies
  • Small Molecules
    • First Generation
    • Second Generation
    • Third Generation
  • Bcr-Abl Inhibitors
  • EGFR Inhibitors
    • First Line
    • Second Line
  • Her2 Inhibitors
  • VEGF Inhibitors
  • Clinics
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Laboratories
    • Academic Laboratories
    • Independent Laboratories
  • Research Institutes
  • Dual-Specificity Protein Kinase
  • Serine/Threonine Kinase
  • Tyrosine Kinase
    • Non-Receptor Tyrosine Kinase (nRTKs)
    • Receptor Tyrosine Kinase (RTKs)
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

This research report categorizes the Tyrosine Kinase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Tyrosine Kinase Inhibitors Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eisai Co. Ltd.
  • Eli Lilly and Company ​
  • F. Hoffmann-La Roche
  • GlaxoSmithKline PLC
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Steris Healthcare Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited ​

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tyrosine Kinase Inhibitors Market, by Application Area
8.1. Introduction
8.2. Non-Oncological Applications
8.2.1. Cardiovascular Diseases
8.2.2. Endocrine Diseases
8.2.3. Immunological Disorders
8.3. Oncology
8.3.1. Breast Cancer
8.3.2. Colorectal Cancer
8.3.3. Leukemia
8.3.4. Lung Cancer
8.3.5. Lymphoma
9. Tyrosine Kinase Inhibitors Market, by Product
9.1. Introduction
9.2. Biologics
9.2.1. Fusion Proteins
9.2.2. Monoclonal Antibodies
9.3. Small Molecules
9.3.1. First Generation
9.3.2. Second Generation
9.3.3. Third Generation
10. Tyrosine Kinase Inhibitors Market, by Drug Class
10.1. Introduction
10.2. Bcr-Abl Inhibitors
10.3. EGFR Inhibitors
10.3.1. First Line
10.3.2. Second Line
10.4. Her2 Inhibitors
10.5. VEGF Inhibitors
11. Tyrosine Kinase Inhibitors Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.3.1. Private Hospitals
11.3.2. Public Hospitals
11.4. Laboratories
11.4.1. Academic Laboratories
11.4.2. Independent Laboratories
11.5. Research Institutes
12. Tyrosine Kinase Inhibitors Market, by Molecule Type
12.1. Introduction
12.2. Dual-Specificity Protein Kinase
12.3. Serine/Threonine Kinase
12.4. Tyrosine Kinase
12.4.1. Non-Receptor Tyrosine Kinase (nRTKs)
12.4.2. Receptor Tyrosine Kinase (RTKs)
13. Tyrosine Kinase Inhibitors Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Americas Tyrosine Kinase Inhibitors Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Tyrosine Kinase Inhibitors Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Tyrosine Kinase Inhibitors Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AstraZeneca PLC
17.3.2. Bayer AG
17.3.3. Boehringer Ingelheim International
17.3.4. Bristol-Myers Squibb Company
17.3.5. Cipla Limited
17.3.6. Eisai Co. Ltd.
17.3.7. Eli Lilly and Company ?
17.3.8. F. Hoffmann-La Roche
17.3.9. GlaxoSmithKline PLC
17.3.10. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
17.3.11. Johnson & Johnson Services, Inc.
17.3.12. Lupin Limited
17.3.13. Novartis AG
17.3.14. Pfizer Inc.
17.3.15. Spectrum Pharmaceuticals , Inc.
17.3.16. Steris Healthcare Pvt. Ltd.
17.3.17. Takeda Pharmaceutical Company Limited ?
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. TYROSINE KINASE INHIBITORS MARKET MULTI-CURRENCY
FIGURE 2. TYROSINE KINASE INHIBITORS MARKET MULTI-LANGUAGE
FIGURE 3. TYROSINE KINASE INHIBITORS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TYROSINE KINASE INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ENDOCRINE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ACADEMIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DUAL-SPECIFICITY PROTEIN KINASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SERINE/THREONINE KINASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-RECEPTOR TYROSINE KINASE (NRTKS), BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RECEPTOR TYROSINE KINASE (RTKS), BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 103. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 104. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 105. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 106. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 107. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 108. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 110. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 112. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 113. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 114. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 115. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 117. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 119. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 120. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 121. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 122. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 126. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 127. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 129. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 156. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 157. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 158. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 161. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 170. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 171. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 172. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 173. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 175. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 176. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 177. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 178. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 179. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 180. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 181. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 182. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 184. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 185. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 186. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 187. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 189. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 190. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 191. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 192. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 193. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 194. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 195. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 198. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 199. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 200. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 201. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 208. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 212. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 213. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 214. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 215. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 217. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 218. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 219. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 220. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 221. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 222. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 226. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 227. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 228. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 229. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 231. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 232. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 233. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 234. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 235. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 236. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 237. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 240. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 241. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 242. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 243. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 245. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 246. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 247. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 254. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 260. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 269. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 270. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 271. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 280. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 282. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 283. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 284. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 285. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 287. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 288. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 289. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 290. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 291. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 292. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 293. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 294. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 296. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 297. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 298. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 299. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 301. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 302. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 303. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 304. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 305. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 306. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 307. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY EGFR INHIBITORS, 2018-2030 (USD MILLION)
TABLE 308. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 310. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY LABORATORIES, 2018-2030 (USD MILLION)
TABLE 311. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 312. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYROSINE KINASE, 2018-2030 (USD MILLION)
TABLE 313. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 314. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 315. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY NON-ONCOLOGICAL APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 316. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 318. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)

Companies Mentioned

  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eisai Co. Ltd.
  • Eli Lilly and Company ​
  • F. Hoffmann-La Roche
  • GlaxoSmithKline PLC
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Spectrum Pharmaceuticals , Inc.
  • Steris Healthcare Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited ​

Methodology

Loading
LOADING...

Related Topics

Related Reports

Bruton Tyrosine Kinase Inhibitors Market - Global Forecast to 2030 - Product Image

Bruton Tyrosine Kinase Inhibitors Market - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Bruton's Tyrosine Kinase Inhibitors Market - Global Forecast to 2030 - Product Image

Bruton's Tyrosine Kinase Inhibitors Market - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Tyrosine Kinase Inhibitors Market Report 2025 - Product Image

Tyrosine Kinase Inhibitors Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Brutons Tyrosine Kinase Btk Inhibitors Market - Product Image

Brutons Tyrosine Kinase Btk Inhibitors Market

  • Report
  • 300 Pages
  • Global
From
Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2025 - Product Image

Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 100 Pages
  • Global
From

About the Tyrosine Kinase Inhibitors Market

Tyrosine Kinase Inhibitors (TKIs) are a class of pharmaceuticals that target tyrosine kinase enzymes, which are involved in the activation of signal transduction pathways that ultimately lead to cell division and proliferation. The dysregulation of tyrosine kinases is a common feature in the pathogenesis of various types of cancer, leading to unchecked cell growth and tumor development. TKIs are therefore an important class of anticancer agents that have reshaped the drug discovery landscape, especially in the treatment of cancers with identifiable molecular targets. In the realm of drug discovery, the market for TKIs has matured with the approval of numerous agents that cover a wide spectrum of targets. Research and innovation focus on improving the efficacy and reducing the side effects, which can include kinome non-selectivity leading to off-target effects. Moreover, the emergence of resistance to first-generation TKIs has spurred the development of second- and third-generation inhibitors that aim to overcome resistance by binding to the kinase domain of mutant enzymes. Several companies are prominent players in the TKI market, frequently associated with pioneering research and the introduction of novel therapeutics. Key names include Novartis, Pfizer, Roche, AstraZeneca, and Bristol Myers Squibb. These companies not only invest heavily in research and development of TKIs but also in the strategic acquisition of smaller biotech firms, partnerships, and collaborations to expand their portfolios and address the diverse needs of patients with cancer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.